MapLight CEO on what investors missed in the biotech’s schizophrenia data
Source: BioPharma Dive - Latest News
Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."